NBI-6024
NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 239480-61-6
- 화학식: C106H180N28O34
- 분자량:2390.73
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nonobese diabetic (NOD) mice[2]
-
Dosage:0.005, 0.05, 0.5, 5, 10, 20 mg/kg
-
Administration:Subcutaneous injection (s.c.)
-
Result:Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 239480-61-6
-
분자량 2390.73
-
화학식 C106H180N28O34
-
Sequence Shortening
SHLVEALALVAGERG
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. [Content Brief]
[2]. Alleva DG, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)